Peter Zdziarski: A Brighter Future for Glanzmann Thrombasthenia Through Gene Therapy
Peter Zdziarski, Vice President and Marketing Director at Glanzmann’s Research Foundation, shared a post on LinkedIn։
“It’s Rare Disease Day, and tomorrow is the official Glanzmann Thrombasthenia Awareness Day.
I was born with GT, and knowing that I may see gene therapy in my lifetime is incredible.
Through every challenge and every win, I wouldn’t change my journey.
The people I’ve met, the knowledge I’ve gained, and the places this path has taken me have shaped who I am, and I’m truly grateful.
Please consider donating to the Medical College of Wisconsin.
Every contribution moves us closer to a future where people with GT have more than just a couple of treatment options.
But a true solution.
A future with fewer antibodies from platelet transfusions, fewer dangerous bleeds, less bruising, and fewer long hospital stays.
The future is bright.
Donate toward gene therapy.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 15:44Andrea Boccatonda: Special Issue on Pulmonary Embolism and Venous Thromboembolism
-
Aug 31, 2026, 15:41Adrien Jossart: Acute Thrombotic Storm Following Single Heparin Bolus
-
Aug 31, 2026, 15:36Bernhard Gerber: Myocardial Platelet Activation Linked to Microvascular Obstruction After STEMI
-
Aug 31, 2026, 15:34Higher Fibrinogen γ′ Linked to Increased Risk of Recurrent Arterial Thrombosis – Journal of Thrombosis and Haemostasis
-
Aug 31, 2026, 15:21Ney Carter Borges: Anticoagulation Versus Antiplatelet Therapy After TAVI ESC 26
-
Aug 31, 2026, 15:13Nahid A. Qushmaq: MicroRNAs as Prognostic Biomarkers in Septic Patients
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?